Home
Storia in 1 fonti
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug - Elicio Thera
Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination studies after mixed Phase 2 results.
Raccontata da
benzinga.com
Timeline cronologica
- ·
Elicio Therapeutics Pancreatic Cancer Study Disappoints - Elicio Therapeutics (NASDAQ:ELTX)
Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase 3 plans.
- ·
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug - Elicio Thera
Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination studies after mixed Phase 2 results.